



# Blood Biomarker Method to differentiate ischemic from haemorrhagic stroke


How to achieve a rapid, accurate biochemical diagnosis of stroke subtypes in the first hours from symptoms onset, qualifying patients for specific treatments, improving significantly patients' outcomes.

## Facts about stroke

Stroke remains one of the most important neurological affection. It represents one of the main leading cause of preventable death worldwide.

Millions worldwide suffer these conditions every year with only a small percentage receiving treatments that are available and effective, due to absence of reliable diagnosis.

### The 10 leading causes of death in the world by percentage




## Current situation

The two main subtypes of stroke are ischemic stroke (IS) and intracerebral haemorrhage stroke (ICH).

Over 80-85% of all strokes are IS caused by a brain artery occlusion, whereas 15-20% are ICH that appear upon an arterial rupture.

An accurate differentiation of both subtypes is critical during acute phase to prescribe the most suitable treatment protocol, which is specific and widely different between IS and ICH.



Brain imaging remains the gold standard for differentiating those stroke subtypes by computerized tomography (CT) or magnetic resonance imaging (MRI). Therefore transfer to a hospital is mandatory, losing precious time to initiate stroke therapy. Moreover, in spite of being highly sensitive,

MRI and CT scans are rarely available in some areas, and cannot be used repeatedly in primary hospital due to the lack of resources.

## ABCDx Solutions For mTBI diagnosis

ABCDx has rights to a combination of proprietary biomarker panels including a novel identified plasma biomarker RBP4 (Retinol-Binding-Protein 4) in combination with GFAP offering the ability to:

- Achieve a rapid, accurate blood sample diagnosis of IS versus ICH immediately upon symptom onset.
- Offer a more rapid and specific decision making capability to any health care site, at the point-of-care.
- Transform the pre-hospital triage and management of stroke patients, allowing the initiation of therapeutic intervention in the ambulance or at a decentralized site.

## Intellectual Property status

ABCDx secured exclusive commercial rights to families of patent applications protecting the use of multiple-parametric tests for patients presenting with symptoms of stroke. This IP places ABCDx as a leading company offering new approaches to assessing clinical decisions and rapidly selecting therapeutic intervention, even in decentralised locations.

*Methods for differentiating ischemic stroke from haemorrhagic stroke. PCT/EP2015/078576*

## Company overview & Licensing opportunity

- ABCDx is a company dedicated to transforming brain injury care by the use of biomarker panel tests for the assessment and indication in patients suffering from mild traumatic injury to stroke and post-stroke complications.
- ABCDx seeks to partner with companies developing and marketing diagnostic tests for appropriate markers, as well as pharmaceutical companies seeking to increase the use of thrombolytic, neuroprotective therapies earlier and to a greater proportion of eligible patients.